WINT News and Press, Windtree Therapeutics Inc. From 06/26/25

Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer underway with validation batch manufacturing expected to begin...

The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other benefits including no increase in hea...

Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting with initiation of Phase 1 High single digit royalties that could total up to $1.5 billion over the life of the drug WARRINGTO...

2025-06-10 11:58:00 ET Diversification is crucial in both life and business, encapsulated by the saying, "Don't put all your eggs in one basket." A former biotech company has embraced this principle, recently shifting its business model to acquire diverse companies. Today, it announced a pi...

2025-06-10 08:12:17 ET More on Titan Environmental Solutions Inc., Windtree Therapeutics Windtree Therapeutics announces resale of 42.17M shares by selling stockholders Windtree Therapeutics regains compliance with Nasdaq listing rules Financial information for Titan...

Windtree continues its transformation entering the rapidly growing $85 billion US environmental services space Refocused strategy is expected to generate $12 million in revenue over the next 12 months Transaction expected to produce a profitable business with growth opportunit...

WARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical ...

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- Windtre...

WARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical c...

2025-05-16 16:25:10 ET More on Windtree Therapeutics Windtree Therapeutics regains compliance with Nasdaq listing rules Windtree shares rise as it announces agreement to become sourcing partner for Evofem Seeking Alpha’s Quant Rating on Windtree Therapeutics ...